BAM15 Research & Scientific Overview

Jump to: Structure | Mechanism | Studies | Pharmacokinetics | Protocols | Limitations | Lead Researcher | References

BAM15 Molecular Structure & Chemical Properties

BAM15 represents a breakthrough in mitochondrial uncoupler design, emerging from structure-activity relationship studies aimed at developing safer alternatives to traditional uncouplers like 2,4-dinitrophenol and FCCP. Originally identified and characterized in 2013 by Kenwood and colleagues, this synthetic compound has become one of the most extensively studied selective mitochondrial protonophores in preclinical research[1]. What distinguishes BAM15 from earlier uncouplers is its unique ability to dissipate the mitochondrial proton gradient without depolarizing the plasma membrane – a critical advancement that dramatically reduces off-target cytotoxicity while maintaining potent metabolic effects[2]. Over the past decade, research spanning metabolic disease, sepsis, cancer, cardiovascular disorders, and aging has positioned BAM15 as a promising candidate for conditions where mitochondrial dysfunction plays a central role.

Chemical Structure

[IMAGE PLACEHOLDER] Insert 2D chemical structure image here Image URL: https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?cid=565708&t=l Alt text: BAM15 2D molecular structure showing oxadiazolopyrazine core Source credit: PubChem Position: Center-aligned below heading

2D molecular structure (Source: PubChem)

Technical Specifications

The compound features a furazan-pyrazine core structure with two fluorophenyl substituents at positions 5 and 6 of the oxadiazolopyrazine ring. The N-H protons on the aniline groups are essential for protonophore activity, enabling proton transport across mitochondrial membranes. Low aqueous solubility is actually advantageous for this compound class, facilitating membrane penetration and mitochondrial targeting[3].

BAM15 Mechanism of Action

BAM15 functions as a lipophilic weak acid that transports protons into the mitochondrial matrix via a pathway independent of ATP synthase, thereby uncoupling oxidative phosphorylation from ATP production. Unlike classical mitochondrial uncouplers, BAM15 operates through selective mitochondrial membrane targeting without affecting plasma membrane potential – a mechanistic distinction that reduces cytotoxicity while preserving metabolic efficacy. This uncoupling mechanism increases oxygen consumption and nutrient oxidation as cells attempt to maintain ATP levels, resulting in increased energy expenditure.

Mitochondrial Proton Gradient Dissipation

BAM15 disrupts the electrochemical proton gradient across the inner mitochondrial membrane, which normally drives ATP synthesis[4]. Key characteristics include:

• Selective mitochondrial targeting without plasma membrane depolarization
• Dose-dependent increases in proton leak across inner mitochondrial membrane
• Enhanced electron transport chain activity to compensate for reduced ATP synthesis efficiency
• Maintained mitochondrial membrane potential until higher concentrations compared to FCCP

Studies using tetramethylrhodamine fluorescence demonstrated that BAM15 causes mitochondrial depolarization without the plasma membrane effects seen with traditional uncouplers, explaining its improved safety profile[1].

AMPK Activation Pathway

Research has shown that BAM15 potently activates AMP-activated protein kinase, a master regulator of cellular energy homeostasis[5]. Mechanistic findings include:

• AMPK activation more potent than metformin or AICAR in vascular smooth muscle cells
• Phosphorylation of acetyl-CoA carboxylase in white adipose tissue following treatment
• Increased expression of genes involved in fatty acid oxidation
• Enhanced mitochondrial biogenesis through PGC-1-alpha upregulation

AMPK activation appears central to BAM15’s effects on lipid metabolism, glucose homeostasis, and vascular function, extending beyond simple thermogenic uncoupling.

Oxidative Stress Modulation

BAM15 influences reactive oxygen species production and mitochondrial antioxidant capacity[6]. Effects observed include:

• Reduction in mitochondrial superoxide production despite increased respiration
• Decreased reactive nitrogen species in septic kidney tissue
• Antioxidant effects through mild uncoupling that reduces electron dwell time
• Protection against ischemia-reperfusion injury linked to ROS reduction

The compound’s ability to increase oxygen consumption while simultaneously reducing ROS generation distinguishes it from traditional uncouplers that often exacerbate oxidative stress.

Mitochondrial DNA Release Inhibition

Studies in sepsis models revealed that BAM15 prevents pathological mitochondrial DNA release into circulation[7]. This mechanism involves:

• Interruption of mtDNA-mtROS positive feedback loop in sepsis
• Reduced circulating mitochondrial DNA levels in animal models
• Protection against mtDNA-triggered inflammatory responses
• Preservation of mitochondrial integrity under stress conditions

Tissue-Specific Metabolic Effects

BAM15 demonstrates preferential distribution and effects in metabolically active tissues[3]. Observed patterns include:

• Primary accumulation in liver and adipose tissue following oral administration
• Enhanced hepatic fatty acid oxidation and lipid depletion
• Increased oxygen consumption most pronounced in hepatocytes
• Adipose tissue remodeling with reduced lipogenic gene expression

[CALLOUT BOX – Highlighted] Key Mechanistic Insight: BAM15’s selective mitochondrial targeting without plasma membrane depolarization represents a significant advancement over traditional uncouplers. This selectivity enables therapeutic-level mitochondrial uncoupling while avoiding the severe cytotoxicity that limited previous compounds, though the precise molecular determinants of this selectivity remain under investigation. [END CALLOUT BOX]

BAM15 Research Applications & Key Findings

Metabolic Disease Research

Obesity and Weight Management Studies

Extensive research in diet-induced obesity models has established BAM15’s anti-obesity effects through increased energy expenditure rather than appetite suppression[3,8]. Key findings include:

• Prevention and reversal of diet-induced obesity in mice fed high-fat diets
• Sustained 15% increase in oxygen consumption during treatment periods
• Fat mass reduction without affecting lean body mass (critical distinction from other interventions)
• Weight loss independent of food intake changes or caloric restriction
• No alterations in core body temperature despite increased metabolic rate

Mice receiving BAM15 at concentrations of 0.1% in diet showed progressive fat loss over 3-6 weeks while maintaining muscle mass and normal feeding behavior[3].

Type 2 Diabetes and Insulin Resistance

Research has demonstrated profound effects on glucose homeostasis and insulin sensitivity[8,9]. Studies showed:

• Reversal of insulin resistance in diet-induced obese mice
• Improved glucose tolerance independent of body weight changes
• Enhanced insulin sensitivity across multiple tissues (liver, muscle, adipose)
• Reduction in fasting glucose and insulin levels
• Improved outcomes in hyperinsulinemic-euglycemic clamp studies

BAM15 treatment normalized glucose metabolism even when administered after obesity was established, suggesting therapeutic potential beyond prevention.

Non-Alcoholic Fatty Liver Disease

Investigations in NAFLD/NASH models demonstrated hepatoprotective effects[10]. Findings include:

• Dose-dependent reduction in liver triglyceride content
• Improved liver enzyme profiles (ALT, AST normalization)
• Reduced hepatic inflammation and fibrosis in STAM mouse model
• Enhanced hepatic fatty acid oxidation
• Depletion of hepatic lipid stores through first-pass metabolism

Studies using structural analogs confirmed that hepatic lipid reduction correlates with the compound’s uncoupling potency.

Cardiovascular System Research

Vascular Function and Blood Pressure

Research examining vascular effects revealed vasorelaxant properties and AMPK-mediated mechanisms[5]. Key observations:

• Relaxation of phenylephrine-induced arterial constriction in rat mesenteric arteries
• Effects independent of endothelium (functional in denuded vessels)
• Vascular AMPK activation stronger than traditional AMPK activators
• Improved endothelial function in hyperglycemic conditions
• Comparable vasoactivity to CCCP and niclosamide but with reduced cytotoxicity

Atherosclerosis Research

Recent studies in atherosclerosis models showed protective effects[11]. Findings include:

• Suppression of atherosclerotic plaque development in ApoE-knockout mice
• Improved serum lipid profiles (reduced cholesterol and triglycerides)
• Inhibition of macrophage foam cell formation
• Reduced inflammatory marker expression
• Protection through IL-1-alpha, SRC, and CSF3 pathway modulation

Renal and Sepsis Research

Acute Kidney Injury Protection

Early BAM15 research established protective effects against ischemia-reperfusion injury[1]. Studies demonstrated:

• Dose-dependent protection from acute renal ischemic-reperfusion injury
• Pretreatment at 1-5 mg/kg reduced plasma creatinine elevation
• Decreased tubular necrosis and leukocyte infiltration
• Protection mechanism linked to reduced ROS generation
• Effects observed with both pretreatment and post-injury administration

Sepsis and Multi-Organ Dysfunction

Research in cecal ligation and puncture models revealed survival benefits[7]. Key findings include:

• Improved survival rates even with 12-hour delayed treatment
• Reduced kidney damage and splenic apoptosis
• Decreased circulating mitochondrial DNA levels
• Interruption of mtDNA-mtROS pathological feedback loops
• Protection extending beyond kidneys to multiple organ systems

Treatment remained effective when initiated after clinical signs of sepsis were evident, suggesting potential clinical utility beyond prophylaxis.

Cancer and Cell Proliferation Research

Acute Myeloid Leukemia Studies

Investigations in AML cell lines and models demonstrated anti-proliferative effects[12]. Research showed:

• Significant inhibition of AML cell proliferation and promotion of apoptosis
• EC50 value of approximately 1.25 micromolar for anti-T. gondii activity
• Induction of mitochondrial dysfunction in leukemia cells
• Selective toxicity favoring cancer cells over normal cells
• Potential synergy with existing chemotherapy approaches

Metabolic Cancer Vulnerabilities

Studies examining cancer cell metabolism revealed selective vulnerabilities to uncoupling. Findings include:

• Enhanced sensitivity in highly glycolytic cancer cells
• ATP depletion effects proportional to metabolic demand
• Reduced tumor growth in various xenograft models
• Potential applications in metabolically active tumor types

[CALLOUT BOX – Highlighted] Critical Research Limitation: Despite extensive preclinical data across multiple disease models, BAM15 has NO published human clinical trials. All efficacy and safety data derive from cell culture and animal studies, primarily in rodents. Human tolerability, optimal dosing, long-term safety, and clinical efficacy remain completely unestablished. Translation from rodent models to humans is particularly uncertain for metabolic interventions. [END CALLOUT BOX]

BAM15 Pharmacokinetics & Metabolism

Absorption & Distribution

BAM15 exhibits favorable oral bioavailability despite being a synthetic small molecule with low aqueous solubility[3]. Pharmacokinetic studies in mice revealed:

• Oral bioavailability of 67% determined by comparing oral versus intravenous administration
• Peak plasma concentrations of approximately 8.2 micromolar following 10 mg/kg oral dose
• Rapid absorption with maximum concentrations achieved within 0.5-1 hour
• Food-based delivery (0.1% in diet) maintained plasma levels of 5-10 micromolar throughout feeding periods
• Sustained elevation in oxygen consumption for 1-2 hours post-gavage, consistent with plasma kinetics

Tissue distribution studies demonstrated preferential accumulation in metabolically active organs. BAM15 concentrated primarily in liver tissue, followed by adipose depots (white and brown fat), with lesser amounts in kidney, heart, and skeletal muscle[3]. Brain penetration was minimal. The low aqueous solubility, rather than being a limitation, facilitates membrane penetration and mitochondrial targeting.

Metabolism & Elimination

The metabolic fate of BAM15 remains incompletely characterized, though available data indicates rapid clearance[3]. Key observations include:

• Plasma half-life of 1.7 hours in mice following intravenous or oral administration
• Gradual clearance from tissues over 4 hours post-administration
• Primary hepatic uptake consistent with first-pass metabolism
• Specific metabolic enzymes and pathways not yet elucidated
• No evidence of toxic metabolite accumulation in repeated dosing studies

Studies using ad libitum dietary administration showed that despite short half-life, continuous consumption maintains effective plasma concentrations. One research group reported a half-life of approximately 3 hours with food-based delivery, suggesting formulation impacts pharmacokinetics[9].

Excretion Pathways

Limited data on elimination routes suggests standard small molecule clearance mechanisms. Available evidence indicates:

• Likely renal and fecal excretion routes based on tissue clearance patterns
• Complete tissue clearance observed within 24 hours
• No bioaccumulation detected in chronic administration studies (up to 8 weeks)
• Hepatic metabolism likely contributes to inactivation before elimination

The compound’s lipophilicity and rapid tissue uptake complicate traditional pharmacokinetic profiling, as mitochondrial accumulation and bioactivity do not directly correlate with systemic concentrations. This pattern is characteristic of lipophilic mitochondrial-targeted compounds.

BAM15 Research Protocols & Administration

Dosing in Published Research

Research investigations have employed diverse BAM15 doses and administration methods depending on study objectives and species:

• Mouse acute studies: 1-100 mg/kg body weight via oral gavage or intraperitoneal injection
• Mouse chronic studies: 0.1% (w/w) admixed in diet, resulting in approximately 85 mg/kg/day consumption
• Mouse ischemia-reperfusion studies: 1-5 mg/kg pretreatment provided dose-dependent protection
• Cell culture studies: 0.1-50 micromolar with optimal uncoupling at 1-20 micromolar range
• Rat vascular studies: Similar concentration ranges as mouse studies

Important: These are experimental doses used in animal studies and cannot be extrapolated to other species due to significant differences in metabolism, mitochondrial physiology, body surface area to mass ratios, and drug clearance rates. Rodents have substantially higher metabolic rates per kilogram body weight compared to larger mammals, making direct dose scaling inappropriate and potentially dangerous.

Administration Routes in Research

Multiple delivery methods have been investigated to assess bioavailability and efficacy:

• Oral gavage – Used for acute pharmacokinetic and efficacy studies; demonstrates 67% bioavailability
• Dietary admixture – Primary method for chronic studies; provides sustained plasma levels via continuous consumption
• Intraperitoneal injection – Employed in some metabolic and protection studies; provides rapid systemic delivery
• Intravenous injection – Used primarily for pharmacokinetic characterization and bioavailability determination

The short plasma half-life necessitates either repeated dosing or continuous dietary administration for sustained effects in chronic studies. Most long-term obesity, diabetes, and NAFLD studies employed food-based delivery at 0.1% concentration.

Common Model Organisms

BAM15 has been studied across multiple experimental systems:

• Mice (C57BL/6J strain) – Primary research model for obesity, diabetes, sepsis, and ischemia studies; majority of published data
• Rats – Used in cardiovascular and vascular function research
• Cell lines – L6 myoblasts, C2C12 myoblasts, AML12 hepatocytes, 3T3-L1 adipocytes, RAW264.7 macrophages, AML cells
• Primary cells – Mouse and rat primary hepatocytes, cardiomyocytes, proximal tubule cells
• Drosophila melanogaster – Recent aging and lifespan studies in fruit fly models
• Isolated mitochondria – Mouse and rat liver mitochondria for direct uncoupling mechanism studies

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite over a decade of preclinical research demonstrating effects across multiple disease models, BAM15 faces substantial translational barriers that prevent clinical application and limit its current utility to laboratory research.

Lack of Human Clinical Data

The most significant limitation is the complete absence of published human clinical trials:

• No Phase I, II, or III trials published in peer-reviewed literature
• No clinical trial registrations found in ClinicalTrials.gov or other databases
• Human safety profile completely uncharacterized
• Optimal human dosing, if any, remains unknown
• Potential for human-specific adverse effects unstudied
• Long-term human tolerability and safety data absent

The gap between extensive rodent efficacy data and zero human data represents a major translational hurdle characteristic of early-stage research compounds.

Mechanistic Understanding Gaps

Fundamental aspects of BAM15’s mechanism remain incompletely characterized:

• Precise molecular basis for mitochondrial selectivity over plasma membrane remains unclear
• Whether uncoupling requires specific mitochondrial proteins or is purely physicochemical
• Contribution of AMPK activation versus uncoupling to observed metabolic effects
• Tissue-specific response variability and its molecular determinants
• Relationship between short plasma half-life and prolonged metabolic effects

Species Translation Uncertainties

Critical questions regarding cross-species applicability include:

• Mitochondrial membrane composition differences between rodents and humans
• Metabolic rate variations affecting dose-response relationships
• Potential for human-specific off-target effects not observed in rodents
• Pharmacokinetic differences in larger mammals versus small rodents
• Long-term safety in species with extended lifespans

Long-Term Safety Considerations

Extended safety profiles remain inadequately studied:

• Chronic use effects beyond 8-week rodent studies unknown
• Impact on mitochondrial biogenesis with prolonged uncoupling unexplored
• Potential for adaptive metabolic responses reducing efficacy over time
• Effects on reproductive function and development incompletely characterized
• Drug interaction potential uncharacterized
• Cancer risk assessment in chronic administration studies not completed

The compound’s effects on rapidly dividing cells and tissues with high proliferative capacity require further investigation given cancer cell studies showing anti-proliferative effects.

Formulation Limitations

Technical challenges related to the compound’s properties:

• Low aqueous solubility complicates pharmaceutical formulation
• Short plasma half-life may necessitate frequent dosing or sustained-release formulations
• DMSO used in research studies not suitable for human administration
• Optimal formulation strategies for clinical translation undeveloped

Regulatory & Competitive Sport Status

FDA Position

BAM15 has not received FDA approval for any indication:

• Classified as an investigational compound for research use only
• Not approved for human or veterinary use
• Not legally available for medical compounding or clinical practice
• No Generally Recognized as Safe (GRAS) determination
• No Investigational New Drug (IND) applications publicly disclosed
• Lacks any established therapeutic indication or dosing guidelines

Research Classification Status

Given the absence of regulatory approval, BAM15 remains restricted to laboratory use:

Research Classification: BAM15 is available exclusively for laboratory research applications. It is not intended for human consumption, medical use, therapeutic applications, or veterinary use. All research must be conducted under appropriate ethical oversight, institutional review board approval where applicable, and in compliance with institutional biosafety and chemical safety protocols. The compound should be handled as a research chemical with unknown human safety profile.

Lead Researcher Spotlight

Dr. Kyle L. Hoehn, PhD

Associate Professor

School of Biotechnology and Biomolecular Sciences

University of New South Wales (UNSW Sydney), Australia

Dr. Kyle Hoehn led the team that first identified and characterized BAM15 as a novel mitochondrial uncoupler in 2013, along with co-investigators including Brandon Kenwood and Webster Santos. His laboratory’s work established BAM15’s unique property of uncoupling oxidative phosphorylation without depolarizing the plasma membrane – a critical distinction that reduced cytotoxicity compared to traditional uncouplers. This discovery, published in Molecular Metabolism, opened new avenues for investigating mitochondrial uncoupling as a therapeutic strategy.

Dr. Hoehn’s research contributions to mitochondrial metabolism and BAM15 include:

• Discovery and initial characterization of BAM15’s selective mitochondrial targeting properties
• Demonstration of BAM15’s protective effects against acute renal ischemia-reperfusion injury
• Structure-activity relationship studies exploring oxadiazolopyrazine derivatives
• Investigations of BAM15’s effects on cellular bioenergetics and metabolic function
• Collaborative studies examining applications in obesity, diabetes, and metabolic disease

His work has been instrumental in establishing BAM15 as one of the most studied mitochondrial uncouplers in contemporary metabolism research, with over 100 subsequent publications by research groups worldwide investigating its potential applications across diverse pathological conditions. Ongoing research continues to explore both the fundamental mechanisms of selective mitochondrial uncoupling and potential therapeutic applications of BAM15 and related compounds.

Disclaimer: This spotlight is provided for educational purposes to acknowledge scientific contributions to BAM15 research. Cenexa Labs has no affiliation with Dr. Hoehn, the University of New South Wales, or any research institutions mentioned, and this information does not constitute an endorsement of any products or services.

References

1. Kenwood, B.M., Weaver, J.L., Bajwa, A., Poon, I.K., Byrne, F.L., Murrow, B.A., Calderone, J.A., Huang, L., Divakaruni, A.S., Tomsig, J.L., Okabe, K., Lo, R.H., Coleman, G., Columbus, L., Yan, Z., Saucerman, J.J., Smith, J.S., Holmes, J.W., Lynch, K.R., Ravichandran, K.S., Uchiyama, S., Santos, W.L., Rogers, G.W., Okusa, M.D., Bayliss, D.A., & Hoehn, K.L. (2014). Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane. Molecular Metabolism, 3(2), 114-123. PubMed
   
2. Kenwood, B.M., Calderone, J.A., Taddeo, E.P., Hoehn, K.L., & Santos, W.L. (2015). Structure-activity relationships of furazano[3,4-b]pyrazines as mitochondrial uncouplers. Bioorganic & Medicinal Chemistry Letters, 25(21), 4858-4861. PubMed
   
3. Alexopoulos, S.J., Chen, S.Y., Brandon, A.E., Salamoun, J.M., Byrne, F.L., Garcia, C.J., Hoehn, K.L. (2020). Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice. Nature Communications, 11(1), 2397. PubMed
   
4. Xiong, G., Zhang, K., Ma, Y., Song, Y., Zhang, W., Qi, T., Qiu, H., Shi, J., Kan, C., Zhang, J., & Sun, X. (2023). BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases. Frontiers in Endocrinology, 14, 1252141. PubMed
   
5. Tai, Y., Li, L., Peng, X., Zhu, J., Mao, X., Qin, N., Gao, J., Gu, Y., Wang, L., Zhang, P., & Tian, Y. (2018). Mitochondrial uncoupler BAM15 inhibits artery constriction and potently activates AMPK in vascular smooth muscle cells. Acta Pharmaceutica Sinica B, 8(6), 909-918. PubMed
   
6. Perry, R.J., Zhang, D., Zhang, X.M., Boyer, J.L., & Shulman, G.I. (2015). Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats. Science, 347(6227), 1253-1256. PubMed
   
7. Jian, M.Y., Alexeyev, M., Cowan, D., Kosmider, B., Potempa, L.A., Cotoia, A., Hauser, C.J., Jahoor, F., Kozar, R.A., Powner, D., & Stewart, R. (2023). BAM15 treats mouse sepsis and kidney injury, linking mortality, mitochondrial DNA, tubule damage, and neutrophils. Journal of Clinical Investigation, 133(7), e152401. PubMed
   
8. Axelrod, C.L., King, W.T., Davuluri, G., Noland, R.C., Hall, J., Hull, M., Dantas, W.S., Zunica, E.R.M., Alexopoulos, S.J., Hoehn, K.L., & Boutagy, N.E. (2020). BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control. EMBO Molecular Medicine, 12(7), e12088. PubMed
   
9. Alexopoulos, S.J., Chen, S.Y., Brandon, A.E., Salamoun, J.M., Byrne, F.L., Garcia, C.J., Hoehn, K.L. (2020). Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice. Nature Communications, 11(1), 2397. PubMed
   
10. Abulizi, A., Cardone, R.L., Stark, R., Lewandowski, S.L., Zhao, X., Hillion, J., Ma, L., Sehgal, R., Alves, T.C., Thomas, C., Kung, C., Wang, J., Siegel, D., Bad, R., Mycek, K., Perry, R.J., Kibbey, R.G., & Shulman, G.I. (2020). Multi-tissue acceleration of the mitochondrial phosphoenolpyruvate cycle improves whole-body metabolic health. Cell Metabolism, 32(5), 751-766. PubMed
    
11. Zhong, C., Huang, Z., Wang, Q., Li, X., Zhang, Y., Zhao, Y., & Chen, X. (2025). Combining RNA-seq, molecular docking and experimental verification to explore the mechanism of BAM15 as a potential drug for atherosclerosis. Scientific Reports, 15(1), 98209. PubMed
    
12. Zhu, S., Dong, Z., Ke, X., Hou, J., Zhao, E., Zhang, K., Wang, F., Yang, L., Xiang, Z., & Cui, H. (2022). The new mitochondrial uncoupler BAM15 induces ROS production for treatment of acute myeloid leukemia. Oxidative Medicine and Cellular Longevity, 2022, 3758978. PubMed
    

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. BAM15 is intended for laboratory research use only.